AAP Releases 2025-2026 Flu Guidance
-
By
July 31, 2025
-
3 min
-
1
Annual influenza vaccination for all children 6 months and older is recommended.
-
2
RIV3 is approved for children 9 years and older.
-
3
Vaccination rates are critically low at 49%.
-
4
Treatment with oseltamivir is preferred for hospitalized children.
-
5
Emphasis on reducing racial/ethnic disparities in vaccination access.
-
6
Live attenuated vaccine is available for at-home use for children 2 years and older.
-
7
Vaccination recommended for pregnant and breastfeeding individuals.
-
The American Academy of Pediatrics has reaffirmed its annual influenza vaccination recommendation for all children aged 6 months and older for the 2025–2026 season, while simplifying antiviral treatment guidance. The new policy allows the recombinant influenza vaccine (RIV3) for children aged 9 years and older but emphasizes that vaccination should not be delayed for specific product requests. Currently, only 49% of U.S. children are vaccinated, highlighting disparities in coverage. The AAP underscores the importance of timely vaccination and antiviral treatments for critical populations.
-
1
Annual influenza vaccination for all children 6 months and older is recommended.
-
2
RIV3 is approved for children 9 years and older.
-
3
Vaccination rates are critically low at 49%.
-
4
Treatment with oseltamivir is preferred for hospitalized children.
-
5
Emphasis on reducing racial/ethnic disparities in vaccination access.
-
6
Live attenuated vaccine is available for at-home use for children 2 years and older.
-
7
Vaccination recommended for pregnant and breastfeeding individuals.
Listen Tab content
